A Phase 2 interventional study of Atacicept 25 mg and Atacicept 75 mg in Relapsing Multiple Sclerosis, sponsored by EMD Serono. Terminated at 48 sites in 17 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-03-20.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 27th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2009, is one of 9 in phase 2, and was the 13th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 664 are open to participants now.
Browse Multiple Sclerosis studies →None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 219 across the 33 interventional studies, 253 across the 38 observational. Of the 70 that completed or were terminated, 42 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).
This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A, subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week subcutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week subcutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to initial and part A treatment allocation/dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects who meet criteria listed below will receive IMP in study 28851:
All subjects must satisfy the following criteria before Extension Study Day 1 (D1-EXT; defined as the first day of dosing in the extension study) to be eligible for treatment with IMP:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Atacicept 25 mg
Drug: Atacicept 75 mg
Drug: Atacicept 150 mg
Drug: Atacicept 150 mg
Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity
TEAEs were defined as AEs with a start date after or on the date of the first DB treatment injection in ATAMS Extension and that occurred anytime after treatment discontinuation, or up to the day before first Rebif® rescue medication injection in ATAMS Extension. A serious TEAE was an AE that resulted in any of the following: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE severity was graded as per Qualitative Toxicity Scale. Local injection site reactions (injection site: pain, redness, itching and swelling) throughout ATAMS Extension, starting after the first trial medication administration. If the subject experienced 1 or more of the above injection site symptoms, these were reported with the AE verbatim term "injection site reaction". For all randomized subjects, there was an option of rescue treatment with Rebif® for 1 year beginning with the first injection of Rebif®).
Time frame: From the first dose of study drug administration up to Week 24
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Blood pressure (systolic and diastolic) was measured after at least 3 minutes resting, with the subject in the seated position.
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Change From Baseline in Vital Signs: Pulse Rate
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Change From Baseline in Vital Signs: Temperature
Time frame: Baseline, Week 2, 4, 8, 12, 16, 20, 24 and 36
Change From Baseline in Electrocardiogram (ECGs)
Time frame: Baseline, Week 12 and 36
Number of Subjects With Worsened Post Baseline Shift in Immunoglobulin A (IgA), IgG and IgM Levels
Number of subjects with shifts from normal Grade (Grade 0) at Baseline to worse value at post-baseline (Grade 1 to Grade 4) according to the following criteria: IgA Grade 0: greater than or equal to (\>=) lower limit normal (LLN) 0.7 gram per liter (g/L); Grade 1: less than (\<) LLN - 0.5 g/L, Grade 2: \<0.5g/L -0.3 g/L, Grade 3: \<0.3 g/L -0.1 g/L, Grade 4: \< 0.1 g/L; IgG Grade 0: \>= LLN (7 g/L), Grade 1: \< LLN - 5 g/L, Grade 2: \<5g/L -4 g/L, Grade 3: \<4 g/L -3 g/L and Grade 4: \< 3 g/L; IgM Grade 0: \>= LLN (0.4 g/L), Grade 1: \< LLN - 0.3 g/L, Grade 2: \<0.3 g/L -0.2 g/L, Grade 3: \<0.2 g/L -0.1 g/L, and Grade 4: \< 0.1 g/L are presented in this outcome measure.
Time frame: Baseline up to Week 36
Number of Subjects With Positive Neutralizing Antibody (NAb)
Time frame: Baseline, Week 12 and 36
Number of Subjects With Clinical Attacks/Relapses
A clinical attack/relapse was defined as the fulfillment of all the following criteria: 1. Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours. 2. Absence of fever or known infection (fever with temperature (axillary, orally, or intra-auriculary) \> 37.5°C/99.5 °Fahrenheit). 3. Objective neurological impairment, correlating with the subject's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Time frame: Baseline up to Week 24
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
Time frame: Baseline, Week 12
Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
Time frame: Week 12
Magnetic Resonance Imaging (MRI) Parameters: Number of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject
Time frame: Baseline, Week 12 and 24
Magnetic Resonance Imaging (MRI) Parameters: Volume of T2 Lesions (New or Enlarging T2 Lesions) Per Subject
Time frame: Baseline, Week 12 and Week 24
Concentrations of Free and Total Atacicept
Time frame: Baseline and Week 12
Free B-Lymphocyte Stimulator (BLyS) and Free A Proliferation-Inducing Ligand (APRIL) Serum Concentrations.
Levels of free APRIL and free BLyS: Free APRIL serum samples were to be analyzed by using a validated enzyme-linked immunosorbent assay (ELISA) with limits of detection of 0.3125 nanogram per milliliter (ng/mL) for free APRIL and free BlyS serum samples were analysed using a validated ELISA with limits of detection of 1.56 ng/mL.
Time frame: Baseline, Week 12 and 36
Pharmacogenetics/Pharmacogenomics Analysis
Gene expression profiling and gene polymorphism identification were to be used to identify putative markers for response to treatment. * Genome-wide gene polymorphism characterization by genome-wide scan. * Targeted gene polymorphism identification of B-Lymphocyte Stimulator (BLyS) , APRIL, (receptor for B cell activating factor of the tumor necrosis factor \[TNF\] family) BAFF-R, (Transmembrane Activator) TACI and (B Cell Maturation Antigen) BCMA and HLA-DRB1 by direct genotyping or sequencing .
Time frame: Day 1 and Week 36
First/last participant (informed consent): 03 March 2009/13 August 2009. Last participant completed: 09 September 2009.
| Milestone | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Started | 16 | 19 | 17 | 22 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 16 | 19 | 17 | 22 |
| Withdrew: Premature termination | 16 | 15 | 14 | 21 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 0 |
| Withdrew: Randomised but not treated | 0 | 2 | 2 | 0 |
TEAEs were defined as AEs with a start date after or on the date of the first DB treatment injection in ATAMS Extension and that occurred anytime after treatment discontinuation, or up to the day before first Rebif® rescue medication injection in ATAMS Extension. A serious TEAE was an AE that resulted in any of the following: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE severity was graded as per Qualitative Toxicity Scale. Local injection site reactions (injection site: pain, redness, itching and swelling) throughout ATAMS Extension, starting after the first trial medication administration. If the subject experienced 1 or more of the above injection site symptoms, these were reported with the AE verbatim term "injection site reaction". For all randomized subjects, there was an option of rescue treatment with Rebif® for 1 year beginning with the first injection of Rebif®).
| Subjects | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Mild TEAEs | 5 | 8 | 8 | 13 |
| Moderate TEAEs | 2 | 4 | 6 | 4 |
| Severe TEAEs | 0 | 0 | 0 | 1 |
| Mild serious TEAEs | 0 | 0 | 0 | 0 |
| Moderate serious TEAEs | 0 | 1 | 0 | 0 |
| Severe serious TEAEs | 0 | 0 | 0 | 0 |
| Mild injection site reaction | 2 | 2 | 5 | 5 |
| Moderate injection site reaction | 0 | 0 | 0 | 2 |
| Severe injection site reaction | 0 | 0 | 0 | 0 |
| Mild infections | 1 | 2 | 4 | 6 |
| Moderate infections | 0 | 1 | 2 | 0 |
| Severe infections | 0 | 0 | 0 | 0 |
| Mild malignancies | 0 | 0 | 0 | 0 |
| Moderate malignancies | 1 | 0 | 0 | 0 |
| Severe malignancies | 0 | 0 | 0 | 0 |
Blood pressure (systolic and diastolic) was measured after at least 3 minutes resting, with the subject in the seated position.
| millimeter of mercury (mmHg) | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| SBP: Week 2 (n = 13, 16, 14, 20) | 2.6 ± 8.3 | -3.0 ± 9.5 | -1.2 ± 10.7 | -0.2 ± 9.8 |
| SBP: Week 4 (n = 15, 14, 12, 21) | 2.1 ± 7.9 | -2.4 ± 13.7 | -5.1 ± 12.6 | -0.1 ± 9.9 |
| SBP: Week 8 (n = 13, 11, 12, 16) | 0.8 ± 10.5 | -2.1 ± 12.0 | -1.1 ± 12.5 | 0.4 ± 11.0 |
| SBP: Week 12 (n = 11, 12, 8, 16) | 3.0 ± 11.7 | -5.8 ± 15.3 | -3.4 ± 10.2 | -0.9 ± 11.3 |
| SBP: Week 16 (n=7, 9, 6, 12) | 5.9 ± 13.4 | -9.0 ± 18.6 | -2.0 ± 12.2 | -2.3 ± 10.0 |
| SBP: Week 20 (n=3, 7, 2, 6) | 2.0 ± 23.1 | -9.7 ± 14.8 | -0.5 ± 0.7 | 3.3 ± 6.0 |
| SBP: Week 24 (n=2, 4, 1, 6) | 5.0 ± 7.1 | -5.0 ± 4.1 | 10.0 ± NA | -5.3 ± 7.7 |
| SBP: Week 36 (n=0, 1, 0, 0) | NA ± NA | -18.0 ± NA | NA ± NA | NA ± NA |
| DBP: Week 2 (n=15, 13, 14, 21) | -2.1 ± 8.2 | -1.9 ± 8.4 | -3.6 ± 10.6 | 0.3 ± 8.6 |
| DBP: Week 4 (n=15, 14, 12, 21) | -0.5 ± 9.0 | -0.4 ± 8.7 | -5.1 ± 9.2 | 0.1 ± 7.7 |
| DBP: Week 8 (n=13, 11, 12, 16) | -2.8 ± 7.7 | -1.6 ± 8.7 | -5.9 ± 10.2 | 0.1 ± 11.0 |
| DBP: Week 12 (n=11, 12, 8, 16) | -3.8 ± 11.1 | -4.8 ± 8.1 | -3.5 ± 9.9 | -2.4 ± 10.3 |
| DBP: Week 16 (n=7, 9, 6, 12) | -1.6 ± 14.2 | -2.9 ± 9.0 | -2.3 ± 4.2 | -1.6 ± 7.7 |
| DBP: Week 20 (n=3, 7, 2, 6) | -2.0 ± 17.1 | -4.4 ± 6.0 | 2.0 ± 4.2 | 3.7 ± 6.3 |
| DBP: Week 24 (n=2, 4, 1, 6) | 0.0 ± 0.0 | -6.3 ± 2.5 | 0.0 ± NA | -1.0 ± 9.8 |
| DBP: Week 36 (n=0, 1, 0, 0) | NA ± NA | -8.0 ± NA | NA ± NA | NA ± NA |
| beats per minute (beats/min) | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Week 2 (n=15, 13, 14, 21) | -2.1 ± 5.1 | -3.5 ± 5.5 | -3.8 ± 10.4 | 3.6 ± 11.4 |
| Week 4 (n=15, 14, 12, 21) | 0.6 ± 8.7 | -0.6 ± 9.2 | 0.7 ± 8.2 | 2.0 ± 8.0 |
| Week 8 (n=13, 11, 12, 16) | -1.7 ± 9.2 | -3.4 ± 9.1 | 1.3 ± 8.7 | 4.4 ± 12.4 |
| Week 12 (n=11, 12, 8, 16) | -0.5 ± 6.2 | 0.7 ± 9.5 | -1.5 ± 8.9 | 4.5 ± 9.5 |
| Week 16 (n=7, 9, 6, 12) | 3.9 ± 4.7 | 1.1 ± 10.5 | -0.2 ± 4.8 | 3.8 ± 9.1 |
| Week 20 (n=3, 7, 2, 6) | -0.3 ± 2.1 | 3.9 ± 8.3 | -5.0 ± 9.9 | 11.0 ± 8.8 |
| Week 24 (n=2, 4, 1, 6) | 2.5 ± 0.7 | -5.3 ± 9.4 | -22.0 ± NA | 9.0 ± 5.3 |
| Week 36 (n=0, 1, 0, 0) | NA ± NA | 7.0 ± NA | NA ± NA | NA ± NA |
| Degree Celsius | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Week 2 (n=15, 13, 14, 21) | -0.09 ± 0.27 | 0.09 ± 0.27 | 0.03 ± 0.21 | -0.07 ± 0.36 |
| Week 4 (n=15, 14, 12, 21) | -0.03 ± 0.24 | 0.05 ± 0.42 | 0.03 ± 0.24 | -0.12 ± 0.31 |
| Week 8 (n=13, 11, 12, 16) | -0.03 ± 0.40 | 0.05 ± 0.10 | 0.03 ± 0.28 | -0.14 ± 0.25 |
| Week 12 (n=11, 12, 8, 16) | 0.02 ± 0.19 | 0.08 ± 0.36 | 0.09 ± 0.57 | -0.15 ± 0.34 |
| Week 16 (n=7, 9, 6, 12) | -0.10 ± 0.21 | 0.17 ± 0.35 | -0.05 ± 0.23 | 0.01 ± 0.42 |
| Week 20 (n=3, 7, 2, 6) | -0.37 ± 0.35 | 0.16 ± 0.56 | -0.25 ± 0.07 | -0.08 ± 0.45 |
| Week 24 (n=2, 4, 1, 6) | 0.05 ± 0.07 | 0.30 ± 0.59 | 0.00 ± NA | -0.07 ± 0.26 |
| Week 36 (n=0, 1, 0, 0) | NA ± NA | 0.70 ± NA | NA ± NA | NA ± NA |
No measurements were reported for this outcome.
Number of subjects with shifts from normal Grade (Grade 0) at Baseline to worse value at post-baseline (Grade 1 to Grade 4) according to the following criteria: IgA Grade 0: greater than or equal to (\>=) lower limit normal (LLN) 0.7 gram per liter (g/L); Grade 1: less than (\<) LLN - 0.5 g/L, Grade 2: \<0.5g/L -0.3 g/L, Grade 3: \<0.3 g/L -0.1 g/L, Grade 4: \< 0.1 g/L; IgG Grade 0: \>= LLN (7 g/L), Grade 1: \< LLN - 5 g/L, Grade 2: \<5g/L -4 g/L, Grade 3: \<4 g/L -3 g/L and Grade 4: \< 3 g/L; IgM Grade 0: \>= LLN (0.4 g/L), Grade 1: \< LLN - 0.3 g/L, Grade 2: \<0.3 g/L -0.2 g/L, Grade 3: \<0.2 g/L -0.1 g/L, and Grade 4: \< 0.1 g/L are presented in this outcome measure.
| Subjects | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| IgA | 1 | 3 | 10 | 9 |
| IgG | 4 | 8 | 12 | 5 |
| IgM | 7 | 6 | 14 | 7 |
A clinical attack/relapse was defined as the fulfillment of all the following criteria: 1. Neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both i) neurological abnormality separated by at least 30 days from onset of a preceding clinical event, and ii) neurological abnormality lasting for at least 24 hours. 2. Absence of fever or known infection (fever with temperature (axillary, orally, or intra-auriculary) \> 37.5°C/99.5 °Fahrenheit). 3. Objective neurological impairment, correlating with the subject's reported symptoms, defined as either i) increase in at least 1 of the functional systems of the Expanded Disability Status Scale (EDSS), or ii) increase of the total EDSS score. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
| Subjects | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| No Relapse | 16 | 16 | 15 | 21 |
| 1 Relapse | 0 | 3 | 2 | 1 |
| 2 Relapse | 0 | 0 | 0 | 0 |
| 3 Relapse | 0 | 0 | 0 | 0 |
| Greater than or equal to (>=) 4 Relapse | 0 | 0 | 0 | 0 |
EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 8 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder, cerebral and other) as well as ambulation. EDSS overall score ranging from 0 (normal) to 10 (death due to MS) was calculated.
| Units on a scale | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at Week 12 | 0.09 ± 0.58 | 0.04 ± 0.97 | 0.50 ± 0.85 | -0.06 ± 0.75 |
The MSFC is a multidimensional clinical outcome measure which consists of three sub-tests; Timed 25-Foot Walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test-3(PASAT-3). The Timed 25-Foot Walk is a quantitative measure of lower extremity function. The 9-Hole Peg Test is a quantitative measure of upper extremity (arm and hand) function. The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Standardized results (Z-scores) of these sub-tests and the overall MSFC Z-score as an average of these three Z-scores was calculated. Higher Z-scores reflect better neurological function and a positive change from baseline indicates improvement. An increase in score indicates an improvement (range -3 to +3).
| z-score | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Change in Multiple Sclerosis Functional Composite (MSFC) Score at Week 12 | 0.21 ± 0.40 | 0.04 ± 0.47 | -0.01 ± 0.24 | 0.07 ± 0.34 |
| Number of lesions per subject | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Baseline (n=16, 19, 17, 22) | 1.1 ± 2.2 | 2.3 ± 5.0 | 0.8 ± 1.4 | 0.9 ± 1.4 |
| Week 12 (n=11, 11, 7, 15) | 0.27 ± 0.47 | 0.64 ± 1.29 | 1.00 ± 1.15 | 2.27 ± 7.16 |
| Week 24 (n=2, 3, 1, 6) | 0.00 ± 0.00 | 2.00 ± 2.00 | 0.00 ± 0.00 | 0.83 ± 0.75 |
| Cubic millimeter | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Baseline (n=16, 19, 17, 22) | 4792.76 ± 3152.56 | 8196.59 ± 8888.74 | 6158.04 ± 7945.59 | 5868.84 ± 7170.81 |
| Week 12 (n=11, 11, 7, 15) | 5604.42 ± 5154.52 | 7634.89 ± 6340.19 | 4934.03 ± 4802.98 | 5365.63 ± 7445.87 |
| Week 24 (n=2, 3, 1, 6) | 1699.60 ± 586.76 | 6814.60 ± 6643.00 | 1931.40 ± 0.00 | 5541.80 ± 5614.73 |
No measurements were reported for this outcome.
Levels of free APRIL and free BLyS: Free APRIL serum samples were to be analyzed by using a validated enzyme-linked immunosorbent assay (ELISA) with limits of detection of 0.3125 nanogram per milliliter (ng/mL) for free APRIL and free BlyS serum samples were analysed using a validated ELISA with limits of detection of 1.56 ng/mL.
No measurements were reported for this outcome.
Gene expression profiling and gene polymorphism identification were to be used to identify putative markers for response to treatment. * Genome-wide gene polymorphism characterization by genome-wide scan. * Targeted gene polymorphism identification of B-Lymphocyte Stimulator (BLyS) , APRIL, (receptor for B cell activating factor of the tumor necrosis factor \[TNF\] family) BAFF-R, (Transmembrane Activator) TACI and (B Cell Maturation Antigen) BCMA and HLA-DRB1 by direct genotyping or sequencing .
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From the first dose of study drug administration up to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atacicept 25 mg (With Loading) | — | 0/16 (0%) | 6/16 (37.5%) |
| Atacicept 75 mg (With Loading) | — | 1/17 (5.9%) | 9/17 (52.9%) |
| Atacicept 150 mg (With Loading) | — | 0/15 (0%) | 8/15 (53.3%) |
| Atacicept 150 mg (Without Loading) | — | 0/22 (0%) | 12/22 (54.5%) |
| Event | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Peripheral EdemaGeneral disorders | 0/16 | 1/17 | 0/15 | 0/22 |
| Event | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) |
|---|---|---|---|---|
| Injection site reactionGeneral disorders | 2/16 | 2/17 | 5/15 | 7/22 |
| NasopharyngitisInfections and infestations | 0/16 | 1/17 | 3/15 | 2/22 |
| HeadacheNervous system disorders | 0/16 | 3/17 | 1/15 | 2/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/16 | 0/17 | 2/15 | 0/22 |
| FatigueGeneral disorders | 0/16 | 2/17 | 0/15 | 0/22 |
| Acute sinusitisInfections and infestations | 0/16 | 0/17 | 1/15 | 0/22 |
| Acute tonsillitisInfections and infestations | 0/16 | 0/17 | 1/15 | 0/22 |
| Herpes zosterInfections and infestations | 0/16 | 0/17 | 1/15 | 0/22 |
| RhinitisInfections and infestations | 0/16 | 0/17 | 1/15 | 0/22 |
| DizzinessNervous system disorders | 0/16 | 1/17 | 1/15 | 0/22 |
Intent-to-treat (ITT) population included all randomized subjects.
| Age, Continuous(years) | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) | Total |
|---|---|---|---|---|---|
| Mean | 39.4 ± 8.4 | 36.8 ± 9.1 | 37.4 ± 11.2 | 34.4 ± 8.6 | 36.8 ± 9.3 |
| Sex: Female, Male(Participants) | Atacicept 25 mg (With Loading) | Atacicept 75 mg (With Loading) | Atacicept 150 mg (With Loading) | Atacicept 150 mg (Without Loading) | Total |
|---|---|---|---|---|---|
| Female | 8 | 12 | 8 | 16 | 44 |
| Male | 8 | 7 | 9 | 6 | 30 |
The record gives a start of Mar 2009, a primary completion of Sep 2009 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 6 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein